The Clinical Observation of the Advanced Liver Cancer Treated by Newcastle Disease Virus
|School||Dalian Medical University|
|Keywords||liver cancer NDV late stage|
Background: Newcastle disease virus (NDV) belonging to Paramyxivirinae, which is one kind of domesticated fowl virus. It had already confirmed that ,in vitro test ,NDV can suppress the tumour cell to grow, induced the tumour cell to apoptosis, when infected by it. In this study we are in order to probe the clinical therapeutic effect and side effect of NDV when it used in liver cancer patient.Method: 60 patients which had been diagnosed to the advanced liver cancer was selected by enhancement CT or the pathology diagnosis, divided into the treatment group and the control group, 30 examples respectively. The treatment group was therapied by the Newcastle disease virus (NDV) and the IL-2 combinedly, and the control group was therapied by IL-2 treatments purily, Through Compared treatment group and control group’s child-pugh graduation, disease inverse amplification factor (CR+PR+SD), Time-To-Progression (TTP), Overall survival time(OS) and the side reaction rate and so on, thus draws the conclusion by analyzes the comparison.Results: Evaluation of treatment group: CR is 0 patient, PR is 2 patients, SD is 15 patients, PD is 13 patients, ORR is 7%,DCR is 57%,TTP is 5.2 months, OS is 6.2 months (2.5-16 months), Side effect rate 0.33% (1 patient); Evaluation of control group: CR is 0 patient , PR is 0 patient, SD is 9 patients, PD is 21 patients, ORR is 0%,DCR is 30% TTP is 4.3 month, OS is 5.4 months (2.2-11 months), Side effect rate is 0% (0 patient). The disease control rate of the treatment group is better than the control group, p <0.05,it’s significantly different analysised statistically.Conclusion: Newcastle disease virus (NDV) have many merits and have high safety in treating mid and late stage liver cancer patientlt;and it can alleviate the clinical symptomsof patients, enhances TTP, but there is no evidence to proved that it can enhance the liver cancer patient’OS.